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Abstract—Inflammatory Bowel Disease (IBD) is an umbrella term for a group of inflammatory diseases of the human gastrointestinal
tract, including Crohn’s Disease (CD) and ulcerative colitis (UC). Changes to the intestinal microbiome, the community of
micro-organisms that resides in the human gut, have been shown to contribute to the pathogenesis of IBD. IBD diagnosis is often
delayed due its non-specific symptoms (e.g. abdominal pain) and an invasive colonoscopy is required for confirmation. Delayed
diagnosis is linked to poor growth in children and worse treatment outcomes. Microbial communities are extremely complex and feature
selection algorithms are often applied to identify key bacterial groups that drive disease. It has been shown that aggregating Ensemble
Feature Selection (EFS) can be used to improve the robustness of feature selection algorithms. The robustness of a feature selector is
defined as the variation of feature selector output caused by small changes to the dataset. Typical feature selection algorithms can be
used to help build simpler, faster, and easier to understand models - but suffer from poor robustness. Having confidence in the output
of a feature selector algorithm is key for enabling knowledge discovery from complex biological datasets. In this work we apply a
two-step filter and an EFS process to generate robust feature subsets that can non-invasively predict IBD subtypes from
high-resolution microbiome data. The predictive power of the robust feature subsets is the highest reported in literature to date.
Furthermore, we identify five biologically plausible bacterial species that have not previously been implicated in IBD aetiology.
Index Terms—Feature evaluation and selection, machine learning algorithms, pattern recognition, medicine
F
1 INTRODUCTION
M ETAGENOMICS is the study of genetic materialsourced from environmental samples, which allows
microbial genomes to be detected and analysed [1]. Metage-
nomics overcomes the flaws that traditional microbiol-
ogy suffers from when identifying and analysing micro-
organisms. Only a small proportion of micro-organisms can
be cultured in growth media in standard laboratory condi-
tions [2]. High throughput sequencing has enabled culture
free detection of microbial communities, and increased the
resolution and power of downstream analysis [3].
Inflammatory Bowel Disease (IBD) is a group of dis-
orders that cause chronic inflammation of the gut. IBD
caused 53,000 deaths worldwide in 2013 and its prevalence
is increasing, particularly in western countries [4]. The
symptoms of IBD are non-specific and diagnosis is typically
confirmed via colonoscopy. However, the invasiveness of
the colonoscopy procedure can introduce a delay in diag-
nosis; delayed diagnosis is common [5] and linked to poor
treatment outcomes, particularly in children [6].
Metagenomic analysis of the intestinal microbiome, the
community of micro-organisms that live in the small in-
testine and colon, requires DNA to be taken from an
environmental sample. For example, to study the human
• B. Wingfield and S. Coleman are with the Intelligent Systems Research
Centre, Ulster University, Derry, United Kingdom (e-mail: wingfield-
b@ulster.ac.uk).
• TM McGinnity is with the School of Science and Technology, Nottingham
Trent University, Nottingham, UK and the Intelligent Systems Research
Centre, Ulster University, Derry, United Kingdom.
• AJ Bjourson is with the Northern Ireland Centre for Stratified Medicine,
Ulster University, Derry, United Kingdom.
Manuscript received XXX-XXX
intestine an intestinal tissue sample or faecal sample could
be taken. DNA is then isolated from the sample, purified,
and sequenced. Large amounts of DNA are present in such
environmental samples, and marker gene surveys are a
cost effective protocol that sequence small sections of DNA
(markers) from such samples. The 16S ribosomal RNA (16S
rRNA) gene is widely used as a universal marker gene for
bacteria, and can be used to create a bacterial census [7]. The
microbial communities present in the human body range
from simple (e.g. skin) to complex (e.g. in the gut), and
metagenomic data reflects this complexity; metagenomic
data sampled from the human gut is highly dimensional
[7]. Highly dimensional data often contains redundant data,
which can hinder knowledge discovery. It is common for
data to be reduced to remove irrelevant features. A popular
approach to data reduction is a selection based strategy,
known as feature selection.
Feature selection is a common preprocessing step in
machine learning applications. Feature selection is useful
for optimising the performance of a model while finding
the smallest subset of features, which can improve model
performance and lower computational complexity [8]. Fea-
ture selection also enables knowledge discovery from high
dimensional data [9]. Domain experts are often interested
in experimentally validating feature subsets, which is an
expensive proposition for biological data. Feature selection
algorithms can return different feature subsets from the
same input data; different feature subsets can be equally
optimal, particularly if a high degree of redundancy is
present in the dataset [10]. Feature selection algorithms can
also return significantly different feature subsets from input
data that has been changed slightly (e.g. by removing a
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sample or after adding noise to a feature). Domain experts
will have more confidence in feature selection algorithms
that generate consistent (robust) feature subsets.
Ensemble Feature Selection (EFS) can generate robust
feature subsets [11]. EFS is inspired by ensemble learning,
where the output of multiple weaker classifiers can be
combined to outperform a single strong model. It has been
shown that combining the output of multiple unstable fea-
ture selectors can create a robust consensus feature ranking
[11]. Typically filter, wrapper, and embedded feature selec-
tion methods that do not consider the robustness of output
have been previously applied to microbiome data [12].
Random Forests have been widely applied for supervised
classification of IBD from microbiome data and the feature
rankings have been reported for knowledge discovery pur-
poses [13], [14], [15]; rankings are often combined with a
recursive feature elimination procedure to generate a feature
subset. Recently an EFS approach was used to generate a
feature subset for the non-invasive prediction of advanced
fibrosis in non-alcoholic fatty liver disease [16]. However,
this approach does not employ an aggregation paradigm
and instead uses an ensemble of Random Forests to select
the top features from an optimal model. This approach
discards the feature ranks from every non-winning model,
and does not consider the robustness of the selected feature
subset.
In this work we investigate if the application of EFS to
high-resolution microbiome count data can improve classi-
fication of IBD from stool samples to enable non-invasive
prediction of IBD subtype. Non-invasive prediction of IBD
subtype has been attempted with some success before [14],
[15] and We also aim to investigate if the robust feature
subsets generate new insights with regards to the compo-
sition of the intestinal microbiome in subjects with IBD. We
employ an EFS technique that uses similarity measures to
aggregate feature ranks into a final consensus list to improve
confidence for future experimental validation. Our rationale
for this approach lies in the nature of the high-resolution
microbiome count data: we define bacteria as specific 16S se-
quence variants called Denoised Sequence Variants (DSVs)
rather than traditional fuzzy clusters of sequences. Recent
work [17] has shown that defining bacteria with the DSV
paradigm provides a host of benefits compared with tradi-
tional fuzzy clusters, described further in Section 2. The DSV
approach has not been applied to date with regards to IBD
classification, and thus our approach provides a promising
area for knowledge discovery.
The remainder of this paper is organised as follows: Sec-
tion 2 describes the background of defining robust feature
subsets, estimating the robustness of a feature subset, EFS,
and the rationale behind using 16S sequence variants rather
than traditional fuzzy clusters. An overview of related re-
search in feature selection applied to metagenomics, feature
selection applied to biological data with regards to IBD, and
the application of classification algorithms to metagenomic
data is also presented in Section 2. Section 3 describes the
publicly available dataset that was analysed, the experi-
mental procedure, and the aggregating EFS algorithm. The
microbial markers generated by EFS and the performance
of the models fitted to the feature subsets are reported,
discussed, and compared with other reported results in
Section 4. Conclusions, limitations, and plans for future
work are discussed in Section 5.
2 BACKGROUND
2.1 Measuring the robustness of feature selectors
The robustness of a feature selector can be defined by the
variation of feature subset output caused by small changes
to the input [18]. In this work the input data were modified
by instance perturbation (removing or adding features) via
resampling with replacement (bootstrapping). Modification
can also be done at the feature level (e.g. by adding random
noise to a feature or group of features) or by a combination
of instance and feature level perturbation.
To measure the overall effect of bootstrapping on feature
stability, [18] proposed a similarity measure based approach.
In this approach the stability was measured by averaging
the pairwise similarity comparison of feature subset output
for k bootstraps, which was defined as:
Sglobal =
2
∑k
i=1
∑k
j=i+1 S (fi, fj)
k (k − 1) (1)
where fi is the feature selector output applied to bootstrap
i, and S (fi, fj) is a similarity measure between fi and fj . In
this work we use the Jaccard Index as a similarity measure:
S (fi, fj) =
|fi ∩ fj |
|fi ∪ fj | =
∑
l I(F
l
i = f
l
j = 1)∑
l I(F
l
i + f
l
j > 0)
(2)
where the function I returns 1 if its argument is true and 0
if its argument is false.
2.2 Aggregating Ensemble Feature Selection
It has been shown that an aggregating EFS approach can
improve the robustness of feature selectors [18]. Ensemble
models are capable of outperforming single models because
if a group of different but equally good hypotheses exist
it is less likely that an ensemble will pick the wrong hy-
pothesis. Furthermore, algorithms can end up in different
local optima enabling an ensemble to better approximate
a true function. Finally it is known that EFS can achieve
greater robustness because it expands the hypotheses space
[19]. EFS has two stages: choosing a set of feature selection
algorithms, and combining the feature subsets into a final
consensus ranked list. In this work we combine the feature
subsets via complete linear aggregation:
f l =
s∑
i=1
f li (3)
where an ensemble contains s feature selectors F1, . . . , Fs.
Each feature selector outputs a feature ranking fi =
f li , . . . , f
N
i . Feature selection must always be combined with
an evaluation of classification performance: domain experts
will not be interested in a stable feature subset that has
poor predictive performance. In this work we apply embed-
ded feature selection algorithms, such as Random Forests
[20] and linear Support Vector Machines (SVM). Embedded
feature selection algorithms provide feature ranking during
training which decreases the computational complexity of
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the EFS process, and embedded feature selection is dis-
cussed further in Section 2.4.1. Random Forests are an en-
semble of decorrelated decision trees [21]; feature rankings
are calculated by randomly permuting a feature in the out-
of-bag samples and calculating the mean change in impurity
or accuracy compared with the out-of-bag rate with unper-
muted features. Linear SVMs can rank features from the
absolute value of the weight vector of the hyperplane [22];
a process known as Recursive Feature Elimination (RFE) is
used to reduce the size of the feature subsets by iteratively
removing the poorest 10% of features until the subset is
empty. In order to effectively evaluate which feature selector
should be chosen for a particular classification problem it
is necessary to use a metric that balances the classification
performance of a feature aggregation and the stability of the
aggregated features. The robustness-performance trade-off
(RPT) [11] is a metric that does this; it is a variant of the
widely used F1-score which is the harmonic mean of the
precision and recall [23]. The RPT is defined as:
RPTβ =
(
β2 + 1
) · Sglobal · P
β2 · Sglobal · P (4)
where P is the prediction accuracy of the classification
model trained on the robust feature subset. β is a parameter
used to weight the relative importance between robustness
and classification performance. In this work we use β = 1
to give equal importance to classification performance and
robustness.
2.3 High resolution microbiome count data
Raw 16S data typically consists of millions of short se-
quences (typically less than 400 nucleotides long). Conven-
tionally the sequence reads are clustered according to fixed
similarity thresholds; typically sequences that are more than
97% similar are binned into an Operational Taxonomic Unit
(OTU), which approximates a bacterial species [3], [24]. A
clustering strategy is required because during amplification
and sequencing significant noise is introduced into the set of
sequence reads [17] (e.g. insertion, deletion, or substitution
sequencing errors). A range of new methods [25], [26], [27]
has been developed that is capable of removing this noise
from the set of sequence reads. These methods are capable
of resolving DSVs to a single-nucleotide resolution, which
removes the need for arbitrary similarity thresholds. These
high-resolution methods have better specificity and sensi-
tivity compared with OTU clustering algorithms [27], and
are better at identifying patterns of community similarity
because DSVs are much less likely to be ecologically mixed
units [25]. It is important to note that although the term OTU
can apply to DSVs (the definition of OTU is intentionally
vague and simply means “the thing(s) being studied” - one
proposed term for DSVs is zero-radius OTU [28]) it is useful
to consistently use different terminology to avoid confusion
as the underlying paradigms are so different (clustering ver-
sus denoising). DSVs offer increased taxonomic resolution,
are defined independently of any reference database, have
consistent labels, and can be re-used across studies [17].
In a conventional clustering approach, units are defined
according to a reference database (reuse is possible but
uncharacterised organisms will be omitted) or in a de novo
fashion (de novo OTUs can include uncharacterised organ-
isms but lack consistent labels and cannot be re-used across
studies [17]). OTUs must be mapped to a taxonomy in order
to provide consistent labels, while DSVs are independent
of taxonomy and represent true biological variation [17].
Predictive microbial markers of disease are only useful if
they can be applied to new data, which is our rationale
for combining the DSV paradigm with an aggregating EFS
strategy. In this work we use the dada2 software package
[27] to implement the DSV paradigm on a publicly available
dataset of treatment-naı¨ve children with IBD.
Microbiome count data consist of an N by M matrix
with N bacterial units (e.g. DSVs) and M samples. The
count data are often normalised into proportions (creating
relative abundance data) or randomly subsampled (rarefac-
tion) to counteract uneven library sizes per sample. The
total sum of sequence reads per sample (library size) can
differ by orders of magnitude across a sequencing run [7],
which distorts measures of bacterial abundance. Both types
of normalisation are flawed and may not be appropriate for
machine learning applications as they do not resolve the
underlying heteroscedasticity present in the data [29] which
has been shown to violate the assumptions of models such
as regression trees [30]. In this work we apply a variance
stabilising transformation [31] to avoid this problem, which
is recommended for machine learning applications [29].
2.4 Related work
2.4.1 Feature selection on metagenomic data
Feature selection has been broadly applied to metagenomic
data to identify a subset of microbes with predictive power
for a particular phenotype, including diabetes [32], obesity
[33], liver cirrhosis [34], non-alcoholic liver cirrhosis [16],
pregnancy [35], psoriasis [36], and IBD [13]. The imple-
mented algorithms cover all the major feature selection
algorithm categories: filter, wrapper, and embedded. The
metagenomic datasets described above are labelled (e.g.
sample A has IBD, sample B is a control), so we only
consider supervised feature selection algorithms, discussed
below. Semi-supervised and unsupervised feature selection
algorithms are available for data that are fully or partially
missing labels or for experiments that aim to investigate the
structure of the data [37].
Filter feature selection algorithms select features without
building a model, and aim to reduce dimensionality by di-
rectly operating on the dataset with criteria such as correla-
tion, redundancy, or information gain [8]. Filter methods are
quick and relatively simple to implement at the expense of
model performance. The Minimum Redundancy Maximum
Relevance (MRMR) feature selection algorithm [38], origi-
nally developed for gene expression data, has been applied
to identify 50 microbial gene markers from the intestinal
microbiome that can be used to successfully classify type 2
diabetes (AUROC: 0.81 [32]). The MRMR approach has also
been applied to identify 15 microbial gene markers from
the gut microbiome, to predict liver cirrhosis with an SVM
(AUROC: 0.918 [34]). A multivariate filter algorithm called
Generalized Local Learning (GLL) was used as the main
feature selection technique for the prediction of psoriaris
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from skin microbiome samples with a good classification
performance (between 0.85 – 0.90 AUROC [36]).
Wrapper feature selection algorithms use a multi-
objective optimisation approach to maximise model per-
formance and minimise feature subset size [8]. Wrappers
search through the space of possible feature subsets using
the constructed model as a performance measure (e.g. clas-
sification accuracy). The search method can range from sim-
ple (combinatorial) to complex (computational intelligence
approaches such as genetic algorithms). Although wrapper
methods provide better results than filter methods they have
a high computational cost and tend to overfit [8]. Genetic
algorithms have been used to identify a subset of microbes
present in the vaginal microbiome that can be used to pre-
dict bacterial vaginosis with an accuracy of between 97-99%
[39]. An exhaustive exploration of bacterial combinations
was used with a ternary regression model to identify a set
of weights that could be used to predict obesity from the gut
microbiome [33]. Although no feature elimination was done
unweighted bacteria could be considered to be unselected.
Embedded feature selection algorithms use internal data
from the classification model to enable feature selection
(e.g. feature rankings of Random Forests). Embedded meth-
ods provide a balance between computational complexity
and performance [8]. A comprehensive review of multi-
class classification and feature selection algorithms found
that embedded feature selection algorithms performed best
across 8 metagenomic datasets [12]. Feature rankings are
sometimes used only for knowledge discovery purposes;
a feature elimination step is not always applied [14], [15].
A Random Forest paired with the Boruta feature selection
algorithm [40] was used to identify a subset of differentially
abundant bacteria present in the vaginal microbiome of
pregnant women [35]. When no feature selection was used
pregnancy could be successfully predicted from the vaginal
microbiome (Scott’s pi index up to 0.8). A Nearest Shrunken
Centroids model [41] was used to select 30 bacterial genera
which could predict IBD with 70% accuracy from the gut
microbiome of subjects in remission [13].
An ensemble of Random Forests has been used to iden-
tify the top features of the best performing model for the
supervised classification of non-alcoholic fatty liver disease
[16]. This is a type of non-aggregating EFS, but is more
similar to the wrapper approach in that a comprehensive
search is undertaken to identify an optimal model. Ensem-
bles are powerful because they fuse decisions [42]. This
approach performs no fusion and instead discards feature
ranks from all non-winning models. These discarded data
could be valuable, and the robustness of the final feature
subset is not considered.
2.4.2 Feature selection on biological data for IBD
Here we consider feature selection techniques applied to
biological data for the purpose of diagnosing IBD. The
data described below include gene expression, proteomic,
metabolomic, and imaging data. A filter was applied to a
proteomics dataset in order to predict IBD at 66% accuracy
from immune response to Escherichia coli proteins [43]. The
dataset consisted of 4,256 Escherichia coli K12 proteins in
a microarray which were tested against blood serum from
around 100 subjects. A univariate statistical test called Sig-
nificance Analysis of Microarrays (SAM) was used to find
proteins that exhibited a statistically significant immuno-
genic response. Significant proteins with a false discovery
rate of 0 were used as input for k-nearest neighbours and
SVM classification models.
Wrapper approaches have been more commonly applied
to biological datasets with lower dimensionality because the
computational complexity of wrapper algorithms does not
scale well for highly dimensional data [8]. An extensive fea-
ture selection pipeline was implemented in order to predict
Crohns Disease Endoscopic Index of Severity (CDEIS) on
a dataset of 30 patients from Magnetic Resonance Imaging
(MRI) images [44]. The implemented approach differs from
the other work described in the literature because human
experts (radiologists) manually performed feature extrac-
tion prior to feature selection. The raw images were first
inspected by radiologists to define a set of 17 features which
were exhaustively searched in a combinatorial manner and
fitted to a linear regression model via a wrapper approach.
An optimal feature subset was able to achieve a correlation
of up to r2 = 0.65. In a metabolomics dataset a genetic algo-
rithm was used to determine optimal spectra that aimed to
identify bowel diseases including IBD from faecal samples
with nuclear magnetic resonance spectroscopy [45]
A two-step filter and embedded feature selection process
was used in a Genome Wide Association Study (GWAS) to
predict IBD [46]. The rationale behind this approach was the
extreme size and dimensionality of the dataset, which con-
sisted of nearly 180,000 single nucleotide polymorphisms
across 44,000 samples. The filtering stage reduced the num-
ber of features from approximately 180,000 to around 10,000.
The embedded stage used L1 (lasso) logistic regression.
L1 penalised models assume only a small proportion of
features will be relevant, and many of the estimated coeffi-
cients can be zero [47]. Feature selection can be achieved by
ignoring features with a coefficient of zero. The two-stage
feature selection process managed to achieve an AUROC
of approximately 0.85 for predicting ulcerative colitis and
Crohns disease.
3 METHODS
3.1 Dataset
We applied a high-resolution microbiome pipeline, de-
scribed further in Section 3.2, to a publicly available
dataset [15] which consisted of 1643 samples collected from
treatment-naı¨ve children and adults diagnosed with IBD
and controls. However, only the paediatric data was used in
this study as there were not enough adults for analysis; chil-
dren were defined as being ≤ 16 years old (the A1 Montreal
classification of IBD [48]). Samples were collected at disease
onset at the time of diagnosis, so IBD was in an active state.
In this work we focus on stool samples in order to develop
a set of robust markers that can be used to non-invasively
predict IBD, so all biopsy samples were discarded, leaving
311 stool samples. Classes were defined according to an
IBD subtype: control versus ulcerative colitis (UC) or control
versus Crohn’s Disease (CD). Although they fall under the
umbrella term IBD the subtypes have significant biological
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differences [49], [50], which is our rationale for choosing an
IBD subtype to define classes.
3.2 Experiment procedure
A reproducible computational workflow was implemented
with Docker and nextflow [51], which is available at
https://github.com/nebfield/crohnsemble. Docker is an
open source container platform. A container bundles to-
gether all of the data, software, and library dependencies
necessary to run a piece of software into an image, similar to
a very efficient virtual machine. Docker helps to improve
reproducible research by solving “dependency hell”, poor
documentation (docker images are self-documenting), and
code rot [52]. The dataset was downloaded using esearch
[53], sra-tools [54], and GNU Parallel [55]. Micro-
biome count data were generated with dada2 [27] and
processed with phyloseq [56] according to a standard op-
erating protocol [57]. A variance stabilising transformation
[31] was applied to the microbiome count data to normalise
the uneven library sizes and heteroscedasticity in the data,
which has been recommended for machine learning appli-
cations [29]. We implemented aggregating EFS, described
further in Section 3.3, using the OmicsMarkeR package
[58]. The Synthetic Minority Over-sampling Technique [59]
(SMOTE) was used to mitigate the class imbalance present
in the dataset. SMOTE is a powerful synthetic sampling
technque that has been successfully applied for a variety
of applications (including biomedical data) [60]. Imbalanced
data can be significantly more difficult to learn, decreasing
model performance [60], [61]. The distribution of microbial
markers was visualised with Venny [62].
3.3 Ensemble feature selection
Prior to applying EFS a simple filter was applied to remove
extremely rare DSVs. DSVs present in less than 5% of
samples were removed, as this study aims to find micro-
bial markers that are present across a broad population.
Prior to EFS 20% of data were retained from the dataset
for independent validation of the final model. In the first
stage of EFS, a portion of the data (20%) is retained in
order to test the performance of the model trained on the
remainder of the data (see Figure 1). The training data
were repeatedly sampled with replacement (bootstrapped).
For each bootstrap bag a SVM and Random Forest were
fit, and recursive feature elimination was applied to each
bag. Feature ranks were extracted across all of the bags,
and merged via complete linear aggregation [11] to form
a single feature ranking list. Each ranked list was combined
across all of the bootstraps to form a final feature subset,
along with frequency and consistency measurements (see
supplement). The RPT was calculated for both models from
the classification performance of the model on the test data
and the global similarity measure across all feature lists.
Random Forests were used to validate the generalisation
ability of the microbial markers as they had the highest RPT
for both CD and UC. All classification results reported are
from the Random Forest model.
Dataset
Introduce instance perturbation.
Create N bootstraps without re-
placement from 80% of data.
Bootstrap1 · · · BootstrapN
Introduce instance perturbation.
Create M bags of data.
Bag1 · · · BagM
Extract feature ranks.
Combine feature rankings across all
bags via complete linear aggregation.
1. Evaluate algorithm robustness via the
pairwise average of feature stability
across all bootstrapped samples;
2. Combine feature ranks across all
bootstrapped samples.
Feature Consistency Frequency
Feature1 c1 = No. of occurrences
across N bootstraps
c1
N
· · · · · · · · ·
Featureq cq = No. of occurrences
across N bootstraps
cq
N
for each bag
for each bootstrap
Fig. 1. Ensemble feature selection workflow.
4 RESULTS AND DISCUSSION
4.1 Comparison of model performance
We begin by evaluating the performance of the classification
models after aggregating EFS is applied to the dataset, as a
robust set of microbial markers must have strong predictive
power to be of value for knowledge discovery and further
investigation by domain experts. The classification and fea-
ture selection ability of Random Forests and SVMs were
IEEE/ACM TRANSACTIONS ON COMPUTATIONAL BIOLOGY AND BIOINFORMATICS 6
TABLE 1
Classification performance of feature subset
Classification problem Data split Sensitivity Specificity PPV NPV
Crohn’s disease Testing 94.5% 90.9% 87.6% 96.1%
Ulcerative colitis 100% 94.5% 94.5% 100%
Crohn’s disease Validation 100% 94.4% 96.4% 100%
Ulcerative colitis 87.5% 100% 100% 92.6%
(a) (b)
Fig. 2. Confusion matrices of models fitted to feature subsets on paediatric validation data; Crohn’s disease (left) and Ulcerative colitis (right). Each
cell contains a percentage of samples assigned to it: light colours represent a small percentage, and darker colours represent a large percentage.
tested. Random Forests were chosen as the final model for
both IBD subtypes as they had the highest RPT (a balanced
metric of classification performance and aggregated feature
robustness, see Table 2). The final models were used to
validate the feature subsets against independent validation
data. The dataset was split into two cohorts according to
IBD subtype; the classification task was to distinguish be-
tween control and disease subjects (two class classification).
Our rationale for this approach stems from the important
biological differences present in the pathophysiology of UC
and CD, which represents an interesting area for knowledge
discovery to be derived from consensus feature subsets.
TABLE 2
An ensemble of Random Forests were chosen for both classification
problems as they had the highest Robustness-Performance Tradeoff
(RPT) measure.
Classification task Model RPT No. features retained
Crohn’s disease Random Forest 0.60 20
SVM 0.58 20
Ulcerative colitis Random Forest 0.70 17
SVM 0.48 17
Non-invasive prediction of both IBD diagnosis and IBD
subtype from stool samples has been previously attempted,
including from this dataset [15]. In [15] IBD was predicted
from biopsies of the terminal ileum (mean AUC: 0.85) and
rectum (mean AUC: 0.78) with good performance. Predic-
tion from stool samples was less successful (mean AUC: 0.66
with much lower consistency). The models used relative
microbial abundance data agglomerated to a genus level. In
[14] classification performance was reported at two different
thresholds: in the first, a sensitivity of 80.3% and a specificity
of 69.7% was reported. The second reported a sensitivity of
45.8% and a specificity of 92.4%. It is important to note that
the patient cohort used in [14] had a mean disease duration
of 34.8 months, while the publicly available dataset used in
this work consists of samples collected at time of diagnosis.
Due to this lengthy disease duration many of the patients in
the cohort had been treated with anti-inflammatory drugs
or other pharmacological interventions which may have im-
pacted the composition of the microbiome — the data used
in this work do not suffer from this limitation. Prediction of
IBD in an adult cohort from biopsies achieved an accuracy of
up to 70% [13] using nearest shrunken centroid classification
[63].
We report here the highest performance of non-invasive
IBD classification from stool samples described in the liter-
ature to date. The classification performance of both feature
subsets was excellent. CD was classified with a Positive
Predictive Value (PPV) of 87.6% in the testing set and 96.4%
in the validation set, and a Negative Predictive Value (NPV)
of 97.1% in the testing set and 100% in the validation set.
UC was predicted with a PPV of 94.5% in the testing set
and 100% in the validation set, and a NPV of 100% in the
testing set and 92.6% in the validation set (see Table 1). This
is significantly better than performance metrics reported in
[13], [14], [15].
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4.2 Robust microbial sequence markers of IBD
Approximately 0.5% of DSVs were retained after a two-
stage filter and aggregating EFS feature selection strategy
(see Table 1). Nearly 4500 DSVs were identified from the
stool samples: a simple filter was applied to remove any
DSVs that were not present in at least 5% of samples. After
this process, aggregating EFS was successfully applied to
the remaining features (around 250 prevalent DSVs). The
overlap of DSVs across IBD subtypes is low - 12.1% of DSVs
were shared across the CD and UC subsets (see Figure 3) -
which reflects the distinct biological differences between the
two subtypes.
The stability of a selected feature can be measured by its
frequency, which is the number of times a feature appears
in each bootstrap divided by the total number of bootstraps
(see Figure 1). Perfectly robust features have a frequency
of 1 while the least robust features will only be present
in a single bootstrap; in this work we used 5 bootstraps
so features with a frequency of 0.2 are the least stable. In
the CD cohort 3 DSVs had a perfect frequency, and in the
UC cohort 4 features had a perfect frequency (see Tables 3–
4). It is important to note that the DSV paradigm reveals
greater differences than would otherwise be reported by a
clustering approach. OTUs are generally capable of being
matched to taxonomic databases at the level of family or
genus [15]; all other IBD classification work agglomerated
OTUs into genus-level relative abundance data to represent
the microbiome. DSVs are capable of resolving separate
bacterial strains (e.g. at a higher than species). However,
because DSVs are relatively short fragments of the full 16S
rRNA gene, taxonomic assignment is sometimes limited to
higher ranks. The agglomeration process will discard bac-
teria that do not meet a defined phylogenetic or taxonomic
threshold. For example, if a genus-level agglomeration is
chosen then OTUs or DSVs that only match to the family
level or higher will be discarded. In this work we chose
not to agglomerate DSVs into specific taxonomic ranks
as biological phenomenon (e.g. IBD subtype) may not be
accurately modelled according to human-defined taxonomic
hierarchies. DSVs have been shown to accurately represent
true biological variation independently of any taxonomic
reference database [17]. Of the most robust features for CD
prediction two could be mapped to genus (Bacteroides and
Haemophilus) and one to family (Lachnospiraceae). One of the
most robust features for UC prediction could be mapped to
species (Bacteroides vulgatus), two to genus (Pediococcus) and
Ersyipelotrichaceae), and one to family (Ruminococcaceae).
4.3 Knowledge discovery
Every denoised microbial sequence marker we have de-
scribed is novel, as previous work has relied on analysis of
fuzzy clusters (see Tables 3–4). We have reported a set of 16S
exact sequence variants (DSVs) that can non-invasively pre-
dict IBD with the highest reported accuracy to date, which
have innate biological meaning and do not rely on refer-
ence databases or taxonomic assignments. The behaviour
of DSVs that match the same species can be markedly
different [25], which demonstrates the limitations of human-
defined taxonomic systems. In order to compare our DSVs
to previous work we have mapped the DSVs to the SILVA
Fig. 3. Venn diagram of DSV microbial marker distribution by cohort (CD:
Crohn’s disease, UC: ulcerative colitis).
taxonomic database [69]. Below we describe elements of the
robust microbial marker set that have been found previously
in the literature, and then move on to bacterial species that
have not been previously implicated in IBD pathogenesis.
It is important to note fuzzy clusters, under normal circum-
stances, are limited to resolving bacteria at high taxonomic
ranks such as Order, Family, or Genus. All of the identified
DSVs have been previously reported in the literature as
biomarkers for IBD at high taxonomic ranks which confirms
that our aggregating EFS process has selected biologically
plausible markers. One of the many advantages of the de-
noising DSV paradigm is increased taxonomic resolution; as
the resolution increases, previously undescribed microbial
markers emerge. The previously described markers below
are gathered from differential abundance statistical tests and
machine learning algorithms (e.g. Random Forest ranks).
The reported biomarkers are from samples gathered from
the entire gastrointestinal tract, including stool, rectal or ileal
biopsies.
We begin by considering the biomarkers originally
reported in [15]: Blautia, Ruminoccous, Pasteurellaceae,
Erysipelotrichales, and Veillonellaceae are repeatedly ob-
served in our set of robust markers [15]. Enterobacteriaceae,
Bacteroidales, and Clostridiales have been repeatedly iden-
tified across the literature as IBD biomarkers [14], [15], [70],
and all are strongly represented in our set of microbial
markers. Fusobacterium has been previously reported as a
biomarker for a number of conditions including IBD [71]
and colorectal cancer [72]; the risk of developing colorectal
cancer in IBD patients is significantly increased [73]. Lach-
nospiraceae, including the Roseburia genus specifically, is
differentially abundant in IBD subjects [70]. Faecalibacterium
prausnitzii is an anti-inflammatory organism and is asso-
ciated with health [68]. Parasutterella excrementihominis has
been observed to be unique to a cohort of treatment-naı¨ve
children [64]. Bacillales [74] and Bifidobacterium [67] have
also been found to be IBD biomarkers.
When the taxonomic resolution is increased, bacterial
species previously unassociated with IBD begin to emerge.
Actinomyces graevenitzii is capable of infecting humans in
combination with other bacterial species. Copathogens such
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TABLE 3
Taxonomy of Robust Microbial Markers of Crohn’s disease.
Frequency Order Family Genus Species Previously
reported?
1 Bacteroidales Bacteroidaceae Bacteroides 3 [15]
1 Pasteurellales Pasteurellaceae Haemophilus 3 [15]
1 Clostridiales Lachnospiraceae 3 [15]
0.8 Actinomycetales Actinomycetaceae Actinomyces graevenitzii 7
0.8 Clostridiales Lachnospiraceae Roseburia 3 [15]
0.8 Clostridiales Peptostreptococcaceae Intestinibacter bartlettii 7
0.8 Clostridiales Ruminococcaceae Ruminococcaceae
UCG-002
3 [15]
0.6 Erysipelotrichales Erysipelotrichaceae Erysipelatoclostridium 3 [15]
0.4 Clostridiales Lachnospiraceae Roseburia inulinivorans 7
0.4 Bacteroidales Bacteroidaceae Bacteroides vulgatus 3 [15]
0.4 Burkholderiales Alcaligenaceae Parasutterella excrementihominis3 [64]
0.4 Pasteurellales Pasteurellaceae Actinobacillus 3 [15]
0.2 Selenomonadales Veillonellaceae Megamonas funiformis 7
0.2 Fusobacteriales Fusobacteriaceae Fusobacterium 3 [15]
0.2 Bacteroidales Bacteroidaceae Bacteroides 3 [65]
0.2 Pasteurellales Pasteurellaceae Haemophilus influenzae or
parainfluenzae
3 [15]
0.2 Clostridiales Ruminococcaceae Ruminiclostridium 5 3 [15]
0.2 Enterobacteriales Enterobacteriaceae Escherichia /Shigella 3 [15]
0.2 Clostridiales Ruminococcaceae Ruminococcus 2 bromii 3 [66]
0.2 Clostridiales Lachnospiraceae Blautia 3 [15]
TABLE 4
Taxonomy of Robust Microbial Markers of ulcerative colitis.
Frequency Order Family Genus Species Previously
reported?
1 Clostridiales Ruminococcaceae 3 [15]
1 Bacteroidales Bacteroidaceae Bacteroides vulgatus 3 [15]
1 Lactobacillales Lactobacillaceae Pediococcus 3 [67]
1 Erysipelotrichales Erysipelotrichaceae Erysipelotrichaceae
UCG-003
3 [15]
0.8 Clostridiales Lachnospiraceae Anaerostipes hadrus 7
0.8 Clostridiales Peptostreptococcaceae Intestinibacter bartlettii 7
0.8 Lactobacillales Streptococcaceae Streptococcus 3 [15]
0.6 Enterobacteriales Enterobacteriaceae 3 [15]
0.6 Clostridiales Lachnospiraceae 3 [15]
0.6 Lactobacillales Streptococcaceae Lactococcus 3 [15]
0.6 Lactobacillales Lactobacillaceae Lactobacillus 3 [15]
0.2 Bacillales Family XI Gemella 3 [15]
0.2 Clostridiales Lachnospiraceae 3 [15]
0.2 Bacteroidales Bacteroidaceae Bacteroides 3 [15]
0.2 Clostridiales Ruminococcaceae Faecalibacterium cf./prausnitzii 3 [68]
0.2 Bacteroidales Bacteroidaceae Bacteroides 3 [15]
0.2 Bifidobacteriales Bifidobacteriaceae Bifidobacterium 3 [15]
as A. graevenitzii rely on other bacterial species to inhibit
the host immune system or to reduce the amount of oxygen
in the local environment before infection can occur [75]; A.
graevenitzii has been implicated in coinfection with tubercu-
losis [75]. In active IBD localised areas of the gut are hypoxic
due to metabolic demand outpacing supply [76]: the IBD
gut appears to provide ideal conditions for A. graevenitzii to
grow. A. graevenitzii is a strong biomarker for CD, with a
frequency of 0.8 (see Tables 3–4). Intestinibacter bartlettii has
only been very recently defined, and its role in the human
gut and human health is uncertain; recent work shows that
I. bartlettii is thought to be resistant to oxidative stress and
is involved with mucus degradation [77]. Oxidative stress
is significantly increased in areas of mucosal inflammation
in IBD [76]. I. bartlettii is a robust biomarker for both of
the CD and UC cohorts, with a frequency of 0.8. Both
Anaerostipes hadrus and Roseburia inulinivorans are lactate
utilising butyrate-producing bacteria, which have been pro-
posed as potential probiotics because butyrate promotes gut
health [78]. A. hadrus is a strong biomarker for UC only
with a frequency of 0.8, and R. inulinivorans is a moderate
marker for CD with a frequency of 0.4. Megamonas funiformis
is a weak biomarker for CD (with a frequency of 0.2 ) and
was originally isolated from human faeces. Its role in the
human gut or health is currently unclear [79]. In summary,
we present a group of previously undescribed biologically
plausible bacterial species that are robust microbial markers
for IBD. The group includes gut health promoting bacteria,
bacterial species that thrive in the inflammatory environ-
ment of an IBD gut and possibly exacerbate the disease, and
other bacterial species with unclear roles in human health.
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5 CONCLUSION
In this paper we reported use of a two-stage feature selec-
tion process of prevalence filtering and aggregating EFS to
identify a robust set of 16S exact sequence variants (DSVs)
that can non-invasively predict IBD. The development of an
accurate non-invasive test for IBD could decrease time to
diagnosis, improving patient outcome. The DSV paradigm
offers a wide variety of benefits over the fuzzy clustering
OTU approach, including increased taxonomic resolution
[17]; previous work has focused on higher taxonomic ranks
(family or genus). In the aggregating EFS paradigm, robust-
ness is defined as the variation of feature selector output
caused by small changes to the input. Merging the output
of multiple weaker feature selectors has been shown to
improve the robustness of feature selectors, in a manner
similar to ensemble learning [18]. We test the classification
performance of the robust feature subsets and find their
predictive power is the highest reported in the literature
to date. The generalisation ability of the robust feature
subset was also verified against a validation dataset (a
20% hold-out partition). A robust feature subset is also
valuable for knowledge discovery which domain experts
can use to plan future experiments. The majority of DSVs in
the feature subset have been previously implicated in IBD,
which validates the biological plausibility of the EFS output.
Here we identify five stable bacterial species that have
not been previously implicated in the pathogenesis of IBD:
Actinomyces graevenitzii, Intestinibacter bartlettii, Megamonas
funiformis, and Anaerostipes hadrus. For the majority of the
novel DSVs it is biologically plausible that they are involved
with the pathophysiology of IBD. Evidence in the literature
has shown the novel DSVs thrive in conditions low in
oxygen, high in oxidative stress, or produce substrates that
promote gut health.
Limitations of this work include that the anatomical
location of the disease was not taken into account. IBD can
be confined to the ileum, rectum, or be present across both.
Our rationale for this was that stool samples will act as a
proxy for the entire gastrointestinal tract, so disease will
naturally be reflected in the composition of the microbiome
sampled from stool. Additionally, there was a significant
imbalance in the size and structure of the dataset in that
relatively few controls were present.
Overcoming these limitations will require expanding the
cohort (in particular creating cohorts with disease limited
to certain areas of the gut) to further validate the robust
microbial markers in future work. Additionally, the micro-
biome does not exist in isolation. Taking into account the
human host (e.g. incorporating data that describe the host
genome and genetic or epigenetic predispositions) could
enable more holistic modelling of the gastrointestinal mi-
crobiome, and applying aggregating EFS to this type of data
could generate new insights into the aetiology of IBD. The
use of DSVs significantly increases the clinical utility of
the identified feature subsets. The specific sequence of the
selected microbes associated with disease are known, and
in future probes could be designed for in vitro or in vivo
validation of the microbial sequence markers. For example,
the relative fluorescence of real-time PCR probes that target
the DSV subsets could be used to measure the abundance
of the DSVs. From these data, new diagnostic tests could be
created and validated.
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